# Catalent, Inc. – Consensus ‘hold’ rating and 19.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/catalent-inc.consensus-hold-rating-and-19.9-upside-potential/4121130968
- Published: 2023-10-26T13:18:33+01:00
- Author: Charlotte Edwards

**Catalent, Inc.** with ticker code (CTLT) have now 14 confirmed analysts covering
the stock with the consensus suggesting a rating of ‘hold’. The target price High/
Low ranges between 58 and 44 and has a mean target at $50.93. Given that the stocks
previous close was at $42.48 this is indicating there is a potential upside of 19.9%.
There is a 50 day moving average of $45.98 and the 200 day moving average is $50.28.
The market capitalization for the company is 7.11B. The stock price for the company
is currently 39.43 USD

 The potential market cap would be $8,522,053,098 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of 23.62 and
a 0.43% return on assets.

Catalent, Inc. is a provider of development and manufacturing solutions for drug,
cell and gene therapies biologics, vaccines, and consumer health products. The Company’s
segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery,
and Clinical Supply Services. Its Biologics segment provides development and manufacturing
for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene
therapies. Its Softgel and Oral Technologies segment provide formulation, development,
and manufacturing services for soft capsules, as well as large-scale manufacturing
of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation
development and manufacturing across a range of technologies along with integrated
downstream clinical development and commercial supply solutions. Its Clinical Supply
Services segment provides manufacturing, packaging, storage, distribution, and inventory
management for, drugs, biologics and clinical trials.

Share on: